EP300 and neoplasm: Thus, the metabolic context (i.e., capacity to store glycogen) may define whether glucose inhibits AMPK, acting as tumor suppressor at initial tumor stages, or induces AMPK acting as tumor promoter at advanced stages to drive EP300/β-catenin interactions.